Page 11234..1020..»

On Second Attempt, SpaceX Launches Rocket At NASA’s Historic Pad – Alabama Public Radio

Posted: February 20, 2017 at 4:42 pm

To paraphrase an age-old saying: If at first you don’t succeed, well, dust off the historic launch pad and try another liftoff.

Not as catchy as the original, perhaps, but certainly fitting for SpaceX, which succeeded Sunday on its second launch attempt at NASA’s Launch Complex 39A, at Kennedy Space Center in Florida. The first attempt, scrubbed Saturday with just 13 seconds before liftoff, was foiled by concerns over an anomaly discovered in the rocket’s steering system.

The issue was “99% likely to be fine,” Elon Musk, founder of the private space company, tweeted Saturday, “but that 1% chance isn’t worth rolling the dice. Better to wait a day.”

On Sunday, however, the launch went smoothly. Not only did SpaceX’s Falcon 9 rocket lift off without a hitch, its first stage also returned to land right back on a platform on Earth. Shortly afterward, the Dragon spacecraft it was carrying detached as planned from the rocket.

While there’s nothing particularly rare about the 5,500 pounds of cargo strapped into that spacecraft which is destined for the International Space Station the pad it took off from has quite a backstory: Launch Complex 39A was the site that sent the first humans to the moon in the 1969 Apollo 11 mission.

It was the pad for a number of NASA’s most important missions from its early days sending people to space, to the three decades of the space shuttle program.

Now the pad, which hadn’t been used since that program ended in 2011, is getting dusted off for a new era “as a spaceport open for use by public and commercial missions to space,” NPR’s Rae Ellen Bichell reported for our Newscast unit.

As we noted Saturday, NASA says SpaceX’s resupply mission packs supplies and materials for more than a few experiments:

“Science investigations launching on Dragon include commercial and academic research investigations that will enable researchers to advance their knowledge of the medical, psychological and biomedical challenges astronauts face during long-duration spaceflight.

“One experiment will use the microgravity environment to grow stem cells that are of sufficient quality and quantity to use in the treatment of patients who have suffered a stroke. A Merck Research Labs investigation will test growth in microgravity of antibodies important for fighting a wide range of human diseases, including cancer.”

Reuters reports that NASA is also carefully monitoring the launch by SpaceX, which it “hired to fly cargo to the station after the shuttle program ended.” The news service says NASA wants “to learn more about SpaceX’s operations before it clears the company to fly NASA astronauts on SpaceX rockets.”

See the original post here:
On Second Attempt, SpaceX Launches Rocket At NASA’s Historic Pad – Alabama Public Radio

Posted in Alabama Stem Cells | Comments Off on On Second Attempt, SpaceX Launches Rocket At NASA’s Historic Pad – Alabama Public Radio

This Biotech ETF Looks Primed To Rally Again – ETF Daily News (blog)

Posted: at 4:42 pm

February 20, 2017 6:42am NASDAQ:IBB

The biotech sector has gotten a lot of attention lately both in the financial markets and in Washington. The sector, which was one of the worst performing areas of the market in 2016 posting a loss of more than 20%, has started posting gains again and is looking like the rally may be poised to continue.

The biggest play in the sector, the iShares Nasdaq Biotechnology ETF (IBB), is up more than 10% on the year (its smaller equal weight counterpart, the SPDR S&P Biotech ETF (XBI), is up over 17%).

The sector has alternatively gotten good and bad news from the White House. For many months, there has been talk of lowering drug prices through open competition or price caps putting pressure on the big drug manufacturers. On the other hand, President Trump spoke recently of his desire to reform the entire drug approval process in order to speed the approval of life-saving medications and cutting the red tape at the FDA. That notion was welcomed by the equity markets even though it received a tepid response from big pharma companies.

One thing working in favor of biotech right now is M&A and the big prize could be Bristol-Myers Squibb (BMY). A StreetInsider article from this week called the company in play and listed Roche (RHHBY), Novartis (NVS), Gilead (GILD) and Pfizer (PFE) all as potential buyers. Acadia Pharmaceuticals (ACAD) could also be up for grabs with Biogen (BIBB) rumored to be a possible bidder. In its quarterly analyst meeting, Amgens (AMGN) CEO Bob Bradway discussed how his company was going to be on the lookout for acquisitions both big and small.

Even Gilead, the big biotech that just caught Wall Street off guard when it significantly lowered 2017 revenue guidance due to weak sales in its hepatitis C drugs, even provided some reason for optimism. The stock dropped roughly 10% on its weak forecast, from a pre-earnings level of around $73 down to a post-announcement low in the $65 area. Since then, however, it has, somewhat surprisingly, begun rallying anew. The stock closed Friday at $70, gaining back nearly of what was lost. Does this signal something of a capitulation point and indicate that buyers are ready to return?

From a technical standpoint, the fund just broke out to the upside from a wedge pattern that has been forming over the past several months.

I wrote earlier this month that I felt the Biotech ETF could close out February above $300 if it could break through the resistance level around $285. It has and now it feels like that $300 level is well within reach.

Despite its rally so far this year, the fund is still about 13% off of its 2016 highs and 26% off of its all-time highs. Valuations in the sector look very reasonable right now as well. Thomson Reuters estimates put the forward P/E of the sector at less than 13, a level it hasnt seen in several years.

Gileads results notwithstanding, the Q4 earnings season has been pretty good for biotech. Big players such as Amgen, Celgene (CELG), Illumina (ILMN) and Vertex Pharmaceuticals (VRTX) all top 10 holdings in the fund popped strongly after announcing earnings. If the sector can continue posting generally good revenue and earnings results and get a little help from the White House along the way, this could be a nice spot to add a few shares.

The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) closed at $294.35 on Friday, up $1.37 (+0.47%). Year-to-date, IBB has gained 10.92%, versus a 5.17% rise in the benchmark S&P 500 index during the same period.

IBB currently has an ETF Daily News SMART Grade of A (Strong Buy), and is ranked #2 of 36 ETFs in the Health & Biotech ETFs category.

About the Author: David Dierking

David Dierking is a freelance writer focusing primarily on ETFs, mutual funds, dividend income strategies and retirement planning. He has spent more than 20 years in the financial services industry and his background includes experience in investment management, portfolio analytics and asset/liability management at both BMO Financial Group and Strong Capital Management.

He has written for Seeking Alpha, Motley Fool, ETF Trends and Investopedia and was also included in the panel for ETFReference.coms 101 ETF Investing Tips from the Experts. He has a B.A. in Finance from Michigan State University and lives in Wisconsin with his wife and two daughters.

You can connect with David on Twitter and LinkedIn. Also be sure to visit his new website, ETFFocus.com.

Tags: biotech david dierking NASDAQ:IBB

Categories: NASDAQ:IBB

See more here:
This Biotech ETF Looks Primed To Rally Again – ETF Daily News (blog)

Posted in Biotechnology | Comments Off on This Biotech ETF Looks Primed To Rally Again – ETF Daily News (blog)

Worldwide Animal Health Biotechnology Market by Analysis of Major Industry Segments 2024 – Digital Journal

Posted: at 4:42 pm

Transparency Market Research Report Added “Animal Health Biotechnology Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 – 2024”

This press release was orginally distributed by SBWire

Albany, NY — (SBWIRE) — 02/20/2017 — Animal Health Biotechnology Market: Overview

Biotechnology utilized in animal healthcare dates back to 19th century when the first vaccines were prepared for its use in animals. Considerable progress in the animal health biotechnology took place recently when biotechnology applications were utilized in both detecting and treating various infectious and parasitic diseases of animals. This has led to the development of a range of applications and procedures, which will benefit both domestic and wild animals. This will also improve the health of various companion animals, help in improving sporting animals’ performance and the productivity of farm animals. However, the globalised trade in live animals, animal products, and their feeds is leading to a continuously increasing threat of infectious diseases worldwide. Thus, to prevent the spread of infectious diseases, the World Organization for Animal Health (OIE) emphasizes the importance of very rapid, accurate, highly specific and sensitive detection and identification of infectious agents; and prompt and effective control of those diseases.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Download PDF brochure for this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11465

Animal Health Biotechnology Market: Current Outlook

Presently, various reagents and diagnostic techniques have been developed, which are more specific, sensitive, rapid, reproducible and robust that have been updated through recent discoveries in biochemistry, immunology and molecular biology (monoclonal antibodies, nucleic probes, DNA amplification and others). The development of new vaccines, such as subunit vaccines, synthetic vaccines, recombinant vaccines and anti-idiotype vaccines, which combine efficacy, innocuity, duration of protection, ease of use, stability and multivalence. The availability of new anti-parasitic and anti-infective agents and immunomodulatory therapeutic agents specifies that biotechnology is continuing to find new applications in the field of animal health. These new vaccines, diagnostic techniques, and therapeutic substances will add to the knowledge, which, in future, will extend to the development of transgenic animals with improved genetic potential and will be more disease resistant and more productive at the same time. Thus, the most important objective of animal health biotechnology is to serve human healthcare as well as its environment at the same time.

Animal Health Biotechnology Market: Drivers

Major factors that will drive the demand from this market mainly includes advancements in cloning and development of transgenic animals, favorable government approval scenarios, and increasing research and development from major firms across the globe. Development of various transgenic animals and cloning will add to the animal’s ability to fight diseases and at the same time it will benefit the human society and environment. This will increase the demand for these animals; hence will contribute towards the growth of animal health biotechnology market in the future. Favorable government policies as well as supportive approval agencies will further help in the growth of this market in future. Major firms across geographies are conducting extensive R&D, which will add to the development of advanced vaccines, therapeutics as well as transgenic animals, will add to the growth of this market in future.

Animal Health Biotechnology Market: Regional Dynamics

Geographically, North America and Europe is expected to dominate the Animal Health Biotechnology market. Major factors that will be responsible for their growth in this market can be high awareness levels of the population about cloning, transgenic products etc. and high investment in research and development activities from both public and private firms in these regions. Asia-Pacific region is also expected to show a rapid growth in this market due to availability of huge livestock population as well as dependency of various regions on animals for their daily activities. Some of the major players operating in the animal health biotechnology market are Bayer AG, Merck & Co., Inc., Pfizer, Inc., Sanofi, and Santa Cruz Biotechnology, Inc.

Browse Full Research Report on Animal Health Biotechnology Market: http://www.transparencymarketresearch.com/animal-health-biotechnology-market.html

About Transparency Market Research Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector – such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Contact: Transparency Market Research 90 State Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com Browse market research blog: https://tmrresearch.blogspot.com/

For more information on this press release visit: http://www.sbwire.com/press-releases/worldwide-animal-health-biotechnology-market-by-analysis-of-major-industry-segments-2024-772649.htm

Excerpt from:
Worldwide Animal Health Biotechnology Market by Analysis of Major Industry Segments 2024 – Digital Journal

Posted in Biotechnology | Comments Off on Worldwide Animal Health Biotechnology Market by Analysis of Major Industry Segments 2024 – Digital Journal

Multiple sclerosis: Stem cell transplantation may halt disease progression – Medical News Today

Posted: at 4:42 pm

New research provides further evidence of autologous hematopoietic stem cell transplantation as an effective treatment for multiple sclerosis, after finding the procedure halted disease progression for 5 years in almost half of patients.

Lead study author Dr. Paolo Muraro, of the Department of Medicine at Imperial College London in the United Kingdom, and colleagues recently reported their findings in JAMA Neurology.

The results come just a fortnight after another study revealed the success of a similar treatment in a small group of patients with relapsing-remitting multiple sclerosis (RRMS).

However, Dr. Muraro and team warn that further trials are needed to determine the efficacy and safety of autologous hematopoietic stem cell transplantation (AHSCT), after a small number of patients died within 100 days of treatment.

In AHSCT, a patient’s own stem cells are harvested. The patient is then subject to high-dose chemotherapy to eliminate any diseased cells.

Next, the harvested stem cells are returned to the patient’s bloodstream, with the aim of restarting normal blood cell production. In simple terms, AHSCT “resets” the immune system.

“We previously knew this treatment reboots or resets the immune system – and that it carried risks – but we didn’t know how long the benefits lasted,” notes Dr. Muraro.

For their study, the researchers assessed data from 25 treatment centers across 13 countries, identifying 281 patients with multiple sclerosis (MS) who underwent AHSCT between 1995-2006. Of these patients, 78 percent had a progressive form of MS.

Using the Expanded Disability Status Scale (EDSS), the team evaluated patients’ progression-free survival at 5 years after treatment and any improvements in MS symptoms.

An EDSS score of zero represents no disability, seven represents the use of a wheelchair, while 10 represents death from MS. At the beginning of the study, patients had an average EDSS score of 6.5.

Overall, the researchers found that 46 percent of patients experienced no disease progression in the 5 years after treatment.

Patients with RRMS – characterized by inflammatory attacks, or “flare-ups,” followed by periods of remission – had the best outcomes, with 73 percent experiencing no worsening of symptoms in the 5 years after AHSCT.

Additionally, patients experienced small improvements in MS symptoms after AHSCT. Patients with progressive MS saw their EDSS score rise by 0.14 a year after treatment, while patients with RRMS experienced a 0.76 increase in their EDSS score.

Patients with a younger age, few immunotherapies prior to AHSCT, and a lower EDSS score at study baseline also showed better outcomes with AHSCT.

While these findings show promise for the use of AHSCT for patients with MS, the team notes that there were eight deaths in the 100 days after AHSCT, which were thought to have been treatment related.

AHSCT involves aggressive chemotherapy, which can severely weaken the immune system and increase susceptibility to infection.

“In this study, which is the largest long-term follow-up study of this procedure, we’ve shown we can ‘freeze’ a patient’s disease – and stop it from becoming worse, for up to 5 years.

However, we must take into account that the treatment carries a small risk of death, and this is a disease that is not immediately life-threatening.”

Dr. Paolo Muraro

Dr. Muraro notes that, importantly, this study did not include a group of MS patients who did not receive treatment, further highlighting the need for more studies assessing the safety and efficacy of AHSCT.

“We urgently need more effective treatments for this devastating condition, and so a large randomized controlled trial of this treatment should be the next step,” he adds.

Read about a study that links vitamin D level at birth to the risk of MS.

See more here:
Multiple sclerosis: Stem cell transplantation may halt disease progression – Medical News Today

Posted in Cell Medicine | Comments Off on Multiple sclerosis: Stem cell transplantation may halt disease progression – Medical News Today

Augmented adoptive cell transfer eradicates solid tumors [PreClinical] – 2 Minute Medicine

Posted: at 4:42 pm

1. Combining tumor-specific T cells and pathogen-based immune stimulation, reenergized adoptive cell transfer (ReACT) targeted and eradicated tumor cells in mice.

2. ReACT led to increased migration of activated T cells to the tumors, a metric that correlated with decreased tumor size.

Evidence Rating Level: 2 (Good)

Study Rundown: Because cancer cells can evade being targeted by the bodys immune system, therapies have been developed to alter the tumors immune microenvironment. One therapy, adoptive cell transfer (ACT), involves engineering T cells to target cells that express tumor-associated antigens (TAAs). Although this therapy has potential, the tumor microenvironment causes inhibition of T cell function, preventing the therapys long-term efficacy. Another approach has been to use pathogens that express TAAs to stimulate the immune system. However, since some tumor cells have altered TAAs, they evade being targeted. In this study, these two approaches were combined into a therapy named ReACT: T cells were engineered to target a TAA as well as a bacterial antigen, and the cells were administered along with a bacterial adjuvant.

When treated with ReACT, a majority of mice with implanted melanoma cells experienced tumor eradication. An increased frequency of T cells in the tumor environment correlated with decreased tumor size. In addition, biomarker levels indicated effective T cell migration and activation. A polyclonal form of ReACT was also tested in a mouse model of melanoma; following tumor eradication in these mice, more tumor cells were introduced but failed to survive, demonstrating an immunological memory response induced by this therapy.

This study demonstrated a new approach for a safer and more efficacious cancer immunotherapy. Future studies will need to more closely mimic a clinical model and provide specific data describing the mechanism of T cell function in this therapy.

Click to read the study in PNAS

Relevant Reading: Cancer Immunotherapy: Strategies for Personalization and Combinatorial Approaches

In-Depth [animal study]: The researchers obtained CD8 T cells that expressed a T cell receptor (TCR) that recognizes a TAA specific to murine melanoma cells. These T cells were then engineered to express a TCR that recognizes the antigen ovalbumin (OVA). In mice with melanoma tumors, this treatment was only effective when the T cells were administered in conjunction with OVA conjugated to Listeria (LM-OVA), a model organism used for pathogen-based cancer vaccines. Seven out of 10 mice experienced complete tumor cell eradication (p

Next, the properties and functions of the ReACT T cells were analyzed. The CD8 T cells were present at a higher frequency in the ReACT-treated mice and this value negatively correlated to tumor size, with an r-value of -0.699. These T cells had an activated phenotype, with an increased expression of CD44 and other transcription factors as well as a decreased expression of inhibitory receptors such as CTLA-4. These T cells also had a high expression of CXCR3, a chemokine receptor involved in migration to tumor cells.

Finally, polyclonal ReACT was tested in mice with melanoma tumors. Tumor-specific CD8 T cells were generated by stimulating them with dendritic cells presenting a pool of TAAs; the cells were additionally engineered to express the OVA TCR, and administered to mice along with LM-OVA. Eleven out of 16 mice experienced complete tumor eradication. These mice were then reintroduced to the same melanoma cell line and were resistant to tumor relapse, demonstrating the establishment of an immunological memory response.

Image: PD

2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

2 Minute Medicines The Classics in Medicine: Summaries of the Landmark Trials is available now in paperback and e-book editions.

This text summarizes the key trials in:General Medicine and Chronic Disease, Cardiology, Critical and Emergent Care, Endocrinology, Gastroenterology, Hematology and Oncology, Imaging, Infectious Disease, Nephrology, Neurology, Pediatrics, Psychiatry, Pulmonology, and Surgery.

See original here:
Augmented adoptive cell transfer eradicates solid tumors [PreClinical] – 2 Minute Medicine

Posted in Cell Medicine | Comments Off on Augmented adoptive cell transfer eradicates solid tumors [PreClinical] – 2 Minute Medicine

Here’s Why Organoids Are a Game Changer in Medical Research – Newsweek

Posted: at 4:42 pm

This article was originally published on The Conversation. Read the original article.

Most of the research behind new medical advances is carried out using either animal tissues or cancer cells. Both tools have their problems: results from animals and humans do not always match up and cancer cells grown for years in laboratories often do not mimic the tissues they originally came from very well. Bridging the gap between whole animals and simple cells can be a challenge during the development of new treatments, but this is beginning to change since scientists have learned how to grow organoids.

Organoids are clusters of cells that organize themselves into mini versions of our organs. They are grown from stem cells, and their use has only become possible with the discovery of the precise conditions needed to keep stem cells alive outside the body. Organoids were first made from intestines but have since been made using many other tissues, including liver, breast and even brain cells. This will allow scientists to better study the development and diseases of these organs.

Try Newsweek for only $1.25 per week

An engineer from CNRS (French Reseach Institut Center) introduces embryonic stem cells in a mouse embryo to set a genetically modified line, Marseille, France, February 9, 2012. Organoidslab-grown miniature versions of organsare proving to be a game changer in the field of medical research. Anne-Christine Poujoulat/AFP/Getty Images

They are grown in a gel that allows them to develop three-dimensionally, so they mimic the architecture of our organs much more realistically than a simple layer of cells. Stem cells from the intestine multiply to form a ball, in which the hollow centeris like the space inside the intestine. The surface of these balls then buds outwardat various points to form pocket-like extensions. This is similar to the intensely folded surface of the gut wall.

Organoids have several advantages over existing approaches. Stem cells are taken from animals or patients and continually multiply so the organoids can be maintained for months. They provide an unlimited supply of material for study, meaning fewer animal studies are required. Making organoids from patients also raises intriguing possibilities for personalized medicine.

In traditional cell cultures every cell is identical but stem cells can form many different cell types, so organoids contain a much more realistic mixture of cells. For example, M cells are specialized cells in the gut wall that act as surveillance posts, capturing bacteria from the gut and showing them to the immune system so it can monitor for danger. Some harmful bacteria exploit this to invade the gut wall. It was previously tricky to grow M cells in the lab for study, but they can be grown in organoids. When added to organoids, Salmonella, a bacterium that causes food poisoning, infected M cells more often than other cell types, suggesting this may be a route of infection in humans.

Some common disease-causing bacteria are surprisingly difficult to grow in the lab, making them hard to study. Clostridium difficile causes numerous cases of diarrhoea every year, a serious condition in frail patients. It has been difficult to grow C. difficile because it requires conditions without oxygen, but researchers in the U.S. have shown that the bug can survive inside intestinal organoids. Bacteria were injected into the centerof intestinal organoids and produced a toxin that made the organoid wall leakier, damaging its ability to act as a barrier.

Organoids made from patient biopsies are allowing us to investigate differences between individuals. Patients with cystic fibrosis show varied responses to treatments. One group of researchers grew organoids from patient biopsies and tested their response to different combinations of drugs. In the future this may be used to quickly find the best treatment for each individual.

Tumors also vary hugely between individuals. Dutch researchers grew organoids from patients with colorectal tumors and identified genetic changes that had occurred in the tumour cells compared to the patients healthy tissue. They were then able to see how these altered the way the cells behaved. They tested anti-cancer drugs on the organoids and could tell which drugs did and did not kill the tumor cells.

Imagine if organoids were routinely made from tumor biopsies and used to identify the best chemotherapy combination for each patient. This is certainly plausible, but the process will first need to be made quicker and cheaper.

All this makes organoids an exciting new tool for researchers. Most work currently focuses on the stomach and intestine, but the technique is quickly expanding to other tissues, such as liver, breast and brain. Organoids will transform the way we conduct medical research, from basic understanding to drug development and personalized therapies. Expect to hear much more about them in the future.

Louise ThompsonisPhD candidate in Molecular and Cellular Physiology at theUniversity of Liverpool.

Read more from the original source:
Here’s Why Organoids Are a Game Changer in Medical Research – Newsweek

Posted in Cell Medicine | Comments Off on Here’s Why Organoids Are a Game Changer in Medical Research – Newsweek

Mayo doc’s stem cell experiment blasts into space – Post-Bulletin

Posted: at 4:42 pm

JACKSONVILLE, Fla. As a boy growing up in Kano, Nigeria, Dr. Abba Zubair dreamed of going to space.

On Sunday, his work hitched a ride with a private rocket blasting off from NASA’s Kennedy Space Center in Cape Canaveral, Fla., on a trip to the International Space Station.

Dr. Zubair, an associate professor of laboratory medicine and pathology at the Mayo Clinic’s Florida campus, prepared a science package involving stem cells as part of a resupply mission to the ISS aboard a SpaceX Falcon 9 rocket.

“It was my first rocket launch view,” said Dr. Zubair, who was on hand to watch and listen to the deafening sound as his experiment rode into space. “It was incredible.”

The stem cells — specialized cells derived from bone marrow come from Dr. Zubair’s lab. Dr. Zubair, according to a report from the Mayo Clinic, specializes in cellular treatments for disease and regenerative medicine. He hopes to find out how the stem cells hold up in space and if they can be more quickly produced in microgravity.

More specifically, Zubair said, he is hoping the research can help in treatment of patients who have suffered a stroke-related brain injury.

“Stem cells are known to reduce inflammation,” he said in a press release. “We’ve shown that an infusion of stem cells at the site of stroke improves the inflammation and also secretes factors for the regeneration of neurons and blood vessels.”

The problem with such a treatment and studying the treatment is generating enough stem cells for the job. Based on current regenerative medicine studies, patients need at least 100 million stem cells for an effective dose. However, reproducing stem cells can be time consuming since the cells naturally limit their numbers.

“Scalability is a big issue,” Dr. Zubair said. “I’ve been interested in a faster way to make them divide.”

And on earth, everything is impacted by gravity, from how high we grow to our bone size and other physiological traits. “So, how can we use the effect of gravity to impact how the cells divide?” he asked.

Experiments that simulate stem cell growth in microgravity, thus far, have shown cells do grow more quickly than experimental controls, he said. So he began working toward getting an experiment into space. The experiment needed to be designed so the crew onboard the space station could run the experiment with some simple training, and Dr. Zubair will be able to watch the experiment in real time via a video connection. “We’ll get some data as early as next week,” he said.

If all goes well, growing stem cells in space something Dr. Zubair admits sounds like a dream of the distant future might become a reality more quickly than many people think.

“There are some companies interested in floating labs,” he said. “I think the future is bright. There are a lot of possibilities in the area of regenerative medicine.”

Read more here:
Mayo doc’s stem cell experiment blasts into space – Post-Bulletin

Posted in Cell Medicine | Comments Off on Mayo doc’s stem cell experiment blasts into space – Post-Bulletin

Researchers cooperate to find risk factors for B cell non-Hodgkin lymphoma – Medical Xpress

Posted: at 4:42 pm

February 20, 2017 by Dov Smith

Non-Hodgkin lymphomas (NHL), tumors which may originate from B or T lymphocytes, account for approximately 3% of the worldwide cancer burden. Most epidemiological studies of NHL have been carried out in North American and European populations, with a few focusing on East Asian populations. Very few epidemiological studies have been conducted on B-cell non-Hodgkin lymphoma (B-NHL) in Middle Eastern populations.

Since Israelis and Palestinians represent genetically and culturally diverse populations living in geographic proximity, research analyzing their risk factors can enrich our understanding of genes and environment in the causation of lymphoma. Despite sharing the same ecosystem, the populations differ in terms of lifestyle, health behaviors and medical systems. Yet both populations report high incidences of NHL, which represents the fifth most common malignancy in Israel and the eighth most common malignancy among West Bank Palestinians. (As of 2012, Israel also ranked first in the world in NHL incidence rates.)

Now, Israeli and Palestinian researchers, led by Prof. Ora Paltiel, Director of the Hebrew University-Hadassah Braun School of Public Health and Community Medicine, and a Senior Physician in Hadassah’s Hematology Department, have conducted a large scale epidemiological study examining risk factors for B-NHL and its subtypes in these two populations.

Recruiting from both the Palestinian Arab and Israeli Jewish populations, the researchers looked at medical history, environmental and lifestyle factors among 823 people with B-cell non-Hodgkin lymphoma (B-NHL) and 808 healthy controls. Using data from questionnaires, pathology review, serology and genotyping, they uncovered some risk factors common to both populations and other factors unique to each population.

The data, reported in the peer-reviewed journal PLOS ONE, showed that in both populations, overall B-NHL was associated with recreational sun exposure, black hair-dye use, a history of hospitalization for infection, and having a first-degree relative with a blood cancer. An inverse association was noted with alcohol use. Some exposures, including smoking and greater-than-monthly indoor pesticide use, were associated with specific subtypes of B-NHL.

The data also pointed to differences between the populations. Among Palestinian Arabs only, risk factors included gardening and a history of herpes, mononucleosis, rubella, or blood transfusion, while these factors were not identified in the Israeli Jewish population. In contrast, risk factors that applied to Israeli Jews only included growing fruits and vegetables, and self-reported autoimmune diseases.

The researchers concluded that differences in the observed risk factors by ethnicity could reflect differences in lifestyle, medical systems, and reporting patterns, while variations by lymphoma subtypes infer specific causal factors for different types of the disease. These findings require further investigation as to their mechanisms.

The fact that risk factors operate differently in different ethnic groups raises the possibility of gene-environment interactions, that is, that environmental exposures act differently in individuals of different genetic backgrounds. But this divergence may reflect differences in diet, cultural habits, socioeconomic, environmental and housing conditions, medical services, exposure to infections in early life or other factors.

This study reflects a unique joint scientific effort involving Israeli and Palestinian investigators, and demonstrates the importance of cooperative research even in politically uncertain climates. Cancer epidemiology will be enriched through the broadening of analytic research to include under-studied populations from a variety of ethnicities and geographic regions.

“Apart from the scientific contribution that this research provides in terms of understanding risk factors for NHL, the study entails an important research cooperation among many institutions. The study provided opportunities for training Palestinian and Israeli researchers, and will provide for intellectual interaction for years to come. The data collected will also provide a research platform for the future study of lymphoma. Epidemiologic research has the potential to improve and preserve human health, and it can also serve as a bridge to dialogue among nations,” said Prof. Ora Paltiel, Director of the Hebrew University-Hadassah Braun School of Public Health and Community Medicine, and a Senior Physician in Hadassah’s Hematology Department.

Explore further: Israeli lifestyle and environment may pose exceptional risks for Hodgkin’s lymphoma

More information: Geffen Kleinstern et al. Ethnic variation in medical and lifestyle risk factors for B cell non-Hodgkin lymphoma: A case-control study among Israelis and Palestinians, PLOS ONE (2017). DOI: 10.1371/journal.pone.0171709

Hodgkin’s Lymphoma (HL) is a common malignancy in early adulthood, accounting for approximately 30 percent of all lymphomas (cancers of the lymph system). The incidence of HL in Israel is among the highest in the world: based …

A new analysis indicates that higher body weight and taller stature during adolescence increase the risk of developing Non-Hodgkin’s Lymphoma (NHL), a type of cancer of the lymphatic system. The findings are published early …

In 2001, Christine Skibola, Ph.D., now a professor of epidemiology at the University of Alabama at Birmingham School of Public Health, joined forces with a small group seeking a large goal discovery of genetic and environmental …

In HIV-infected patients receiving antiretroviral therapy (ART), chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) coinfection is associated with an increased risk for non-Hodgkin’s lymphoma. The findings are published …

Many of the toughest decisions faced by cancer patients involve knowing how to use numberscalculating risks, evaluating treatment options and figuring odds of medication side effects.

The metabolic state of tumor cells contributes to signals that control their proliferation. German biochemist and Nobel Prize laureate Otto H. Warburg observed in the 1920s that tumor cells radically change their metabolism. …

Whether to screen? How often? At what age? At what cost?seem to readily breed conflicting opinions and public confusion. What’s needed is rigorously produced evidence. That’s where Constantine Gatsonis, chair of the Department …

A new study that confirms the role of a protein called PAK4 in the movement and growth of pancreatic cancer cells could help researchers find new ways to tackle the disease.

Researchers in Germany have discovered that a tumor suppressor protein thought to prevent acute myeloid leukemia (AML) can actually promote a particularly deadly form of the disease. The study, “RUNX1 cooperates with FLT3-ITD …

Less aggressive cancers are known to have an intact genomethe complete set of genes in a cellwhile the genome of more aggressive cancers tends to have a great deal of abnormalities. Now, a new multi-year study of DNA …

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Go here to read the rest:
Researchers cooperate to find risk factors for B cell non-Hodgkin lymphoma – Medical Xpress

Posted in Cell Medicine | Comments Off on Researchers cooperate to find risk factors for B cell non-Hodgkin lymphoma – Medical Xpress

R3 Stem Cell Now Offering Regenerative Medicine Treatment in Las … – PR Web (press release)

Posted: at 4:42 pm

Top Stem Cell in Las Vegas and Henderson NV (844) GET-STEM

Las Vegas, Nevada (PRWEB) February 20, 2017

R3 Stem Cell is now offering regenerative medicine treatment in Las Vegas and Henderson Nevada. Treatments have helped many patients avoid surgery and improve their lives dramatically. R3 has partnered with Dynamic Stem Cell Therapy to offer treatment for all types of conditions. Call (844) GET-STEM for more information and scheduling.

Regenerative medicine therapy with stem cells has become mainstream, and the pioneers at Dynamic Stem Cell Therapy are experts. The conditions treated include arthritis, tendonitis, sports injuries, ligament injuries along with a host of systemic issues such as COPD, CHF, Lupus, Rheumatoid Arthritis, Crohns Disease, Diabetes and many more.

The Las Vegas stem cell center uses the patients adipose tissue, and concentrates the stem cells in a same day treatment. The treatment is offered either as an injection or an infusion, depending on the need.

The therapy works great for helping patients avoid the need for potentially risky surgery, such as joint replacement or tendonitis surgery. Not only does the procedure include stem cells, but also growth factors along with other healing agents.

Along with the adipose stem cell therapy, the Las Vegas stem cell doctors utilize platelet rich plasma therapy, known as PRP therapy for short. The combination of the two augment the capability of repair.

In addition to bone and joint conditions along with organ issues, Dynamic offers cosmetic procedures as well. This includes the Vampire facelift along with hair restoration that works great from platelet rich plasma therapy.

Over 85% of patients benefit from the regenerative medicine procedures. Call (844) GET-STEM for more information and scheduling with the top stem cell therapy in Las Vegas.

Share article on social media or email:

Read the original here:
R3 Stem Cell Now Offering Regenerative Medicine Treatment in Las … – PR Web (press release)

Posted in Cell Medicine | Comments Off on R3 Stem Cell Now Offering Regenerative Medicine Treatment in Las … – PR Web (press release)

New Partnership to Advance Production Standards in Biomanufacturing – Research Horizons

Posted: at 4:42 pm

Posted February 20, 2017 Atlanta, GA

The Georgia Institute of Technology will play a key role in a new public-private partnership to help establish best practices and eventual industry-wide standards for the production of therapies using living cells to treat a range of conditions.

The new partnership aims to advance techniques to process, measure and analyze cell, gene, tissue-engineered, and regenerative medicine products, as well as cell-based drug discovery products.

We are poised to make a significant impact in how cells and regenerative medicine products are manufactured across the world through this new strategic partnership, said Krishnendu Roy, Robert A. Milton Chair and professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University.

Roy will serve as one of the Charter Board Members for the new International Standards Coordinating Body (SCB), which was recently established in coordination with National Institute of Standards and Technology (NIST) and Alliance for Regenerative Medicine (ARM).

Georgia Tech has already taken a leadership role in development of best practices and analytical standards that will impact biomanufacturing and innovation through the national roadmap on cell manufacturing developed by the National Cell Manufacturing Consortium (NCMC) and the newly established Marcus Center for Therapeutic Cell Characterization and Manufacturing (MC3M), Roy said.

Compared to traditional pharmaceuticals, which are made primarily through chemical processes, biological medicines, also known as biopharmaceuticals, are much more challenging to produce. With medicines like cell-therapies, gene therapies and engineered tissues, finding ways to produce larger quantities at a time while ensuring high-quality and safety is a key challenge.

The SCBs long-term mission is to efficiently and effectively support sector standards development to accelerate product development and scalability, and streamline regulatory submission review and approval, said Robert A. Preti, chairman of ARM and president of cell manufacturing industry partner PCT, a Caladrius Company.

The new standards initiative comes on the heels of the establishment of two National Manufacturing Innovation Institutes announced last December. One, the Institutes for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), which the U.S. Department of Commerce is supporting with a five-year, $70 million grant is a consortium of more than 150 companies, academic institutions and other organizations focused towards working on improving the way biopharmaceuticals are produced, with a goal of bringing down costs and finding ways to get the drugs into the hands of clinicians and patients faster. The second, Advanced Regenerative Manufacturing Institute (ARMI) is funded by the Department of Defense and focuses on biofabrication of engineered tissues as replacement of damaged and diseases organs as well as for therapeutics development. Georgia Tech is poised to play key roles in these initiatives as well.

These synergistic national and international activities further establish Georgia Tech as a leading academic institution in the biopharmaceutical area, Roy said. In January 2016, Georgia Tech announced the Marcus Center as a research center devoted to developing processes and techniques to manufacture living cells. The center was made possible by a $15.7 million grant from the Atlanta-based Marcus Foundation. This center intends to work closely with NIIMBL and ARMI to further leverage these unique private-public partnerships and develop transformative technologies to bring cell-based therapies and regenerative medicines to clinic faster and at a lower cost.

Read the rest here:
New Partnership to Advance Production Standards in Biomanufacturing – Research Horizons

Posted in Cell Medicine | Comments Off on New Partnership to Advance Production Standards in Biomanufacturing – Research Horizons

Page 11234..1020..»